title: Rapamycin and cyclosporine A treatment: a novel regimen to prevent chronic allograft rejection in sensitized hosts.
authors.affiliation: Harvard Medical School, Division of Immunology, Beth Israel Hospital, Boston, MA 02115, USA.
authors.forename: B
authors.initials: B
authors.lastname: Wasowska
authors.forename: W W
authors.initials: WW
authors.lastname: Hancock
authors.forename: K
authors.initials: K
authors.lastname: Onodera
authors.forename: S
authors.initials: S
authors.lastname: Korom
authors.forename: T H
authors.initials: TH
authors.lastname: Stadlbauer
authors.forename: X X
authors.initials: XX
authors.lastname: Zheng
authors.forename: T B
authors.initials: TB
authors.lastname: Strom
authors.forename: J W
authors.initials: JW
authors.lastname: Kupiec-Weglinski
mesh_terms: D001161:Arteriosclerosis / Q000473:pathology / Q000503:physiopathology; D018932:Chemokine CCL2 / Q000096:biosynthesis; D018946:Chemokine CCL5 / Q000096:biosynthesis; D002908:Chronic Disease; D016572:Cyclosporine / Q000627:therapeutic use*; D016207:Cytokines / Q000096:biosynthesis; D006084:Graft Rejection / Q000517:prevention & control*; D006085:Graft Survival; D016027:Heart Transplantation / Q000276:immunology* / Q000473:pathology; D006801:Humans; D007114:Immunization; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D011090:Polyenes / Q000627:therapeutic use*; D011183:Postoperative Complications; D020123:Sirolimus; D014158:Transcription, Genetic; D014184:Transplantation, Homologous
chemical_list: D018932:Chemokine CCL2; D018946:Chemokine CCL5; D016207:Cytokines; D007166:Immunosuppressive Agents; D011090:Polyenes; D016572:Cyclosporine; D020123:Sirolimus